Opioid Use Disorder Treatment Market

Opioid Use Disorder Treatment Market Snapshot (2023 to 2033)

The global opioid use disorder treatment market is expected to attain an impressive valuation of USD 3.07 billion in 2023 and is projected to reach USD 8.4 billion by 2033, trailing a CAGR of 10.5% during the forecast period.

A growing number of treatment centers, with mergers with private recovery institutions to aid in the extension of treatment access to a wide range of people is expected to push market growth. Moreover, increasing initiatives and funding by government for the awareness and treatment of opioid use disorder is estimated to contribute to market expansion during the forecast period.

On the other hand, rising government investments in technology and telecommunication to fortify the healthcare infrastructure is anticipated to propel market growth.

Report Attribute	Details
Expected Market Value (2023)	USD 3.07 billion
Anticipated Forecast Value (2033)	USD 8.4 billion
Projected Growth Rate (2023 to 2033)	CAGR 10.5%

2018 to 2022 Opioid use disorder treatment management Demand Analysis vs. Forecast 2023 to 2033

The market for opioid use disorder treatment was worth USD 2.1 billion in 2018, while growing at a CAGR of 7.89 % during the historical period. One of the key factors propelling market’s growth is the increase in drug awareness campaigns and associated preventive programs. In many nations, it includes improved patient awareness, a higher percentage of treatment-seeking with enhanced government participation, and encouragement to combat substance misuse.

Additionally, an increasing number of treatment centers with partnerships with private recovery institutions are entering the market, assisting in the extension of treatment access to a broader range of people in society which is expected to contribute to market’s growth in the coming years.

Also, the high prevalence of comorbid illnesses is accountable for wrong prescription drugs. Therefore, the rising consumption of non-medical prescription drugs and increasing overdose deaths are expected to propel market growth during the forecast period. Considering these factors, the demand for Opioid use treatment products is projected to garner a valuation of USD 8.4 billion by end of the forecast period, while exhibiting a CAGR of 10.5%.

Which are Some Prominent Drivers of the Opioid use disorder treatment market?

Adoption of buprenorphine patches propelling market expansion

The increasing consideration of buprenorphine patches as an effective treatment mode is fueling the market growth. Buprenorphine patches are becoming gradually popular as an effective treatment for opioid use disorder, which is expected to propel opioid use disorder market. These patches containing buprenorphine are regarded as a cutting-edge method for treating these disorders.

Likewise, transdermal patches offer numerous benefits over other kinds of treatment, such as injections, including the most pleasant drug delivery system, excellent pain relief, and self-administration of drug. Also, growing adoption of key strategies such as collaboration, acquisition, agreement, and partnership by opioid industry of opioids use disorder is leading to market expansion. For example, in February 2019, Indivior PLC, a pharmaceutical company, made a revelation about an agreement with Alvogen Pine Brook LLC, a pharmaceutical company for sell of generic buprenorphine and naloxone sublingual film product.

What are the Challenges Projected to be Faced by the Market?

Side-effects from drug administration to restrain market expansion

One of the restraining factors that is expected to restrain growth of Opioid use disorder treatment market is the side effects that might arise from the drugs administration for treatment of opioid addiction. Some of the typical side-effects from these drugs include vomiting, bladder pain, abdominal cramps, diarrhea, respiratory complications, bone or joint pain, muscle aches, and constipation which are expected to hold back market growth. Moreover, in few certain severe cases of adverse reaction, the patient may also suffer from psychological problems such as depression. Thus, restricting market expansion.

Region-Wise Insights

What are the growth prospects in North America?

North America to dominate the market with maximum share

North America is expected to dominate the market of Opioid use disorder treatment by garnering a market share of 48% by end of the forecast period. This region is estimated to grow with a CAGR of 8.2% during the projected period. It is set to remain at the forefront because of the presence of reputed pharmaceutical companies in this region. At the same time, the increasing government initiatives for handling the growing opioid dependency would fuel the market for opioid use disorder in the forthcoming years.

Also, the market in United States is further anticipated to witness launch of new products entering the market in the forecast period, such as Braeburn’s CAM-2038-additional buprenorphine subcutaneous formulation for, potentially, monthly injection. If approved, it will have a benefit over Sublocade-Sublocade needs an initiating treatment with oral buprenorphine for seven days until dose stabilization, while CAM-2038 will not have this prerequisite. It is projected to further boost the North America opioid use treatment market.

What is the growth outlook in East Asia?

East Asia driving growth with fastest CAGR

East Asia was the second-largest contributor in opioid use disorder treatment market in 2022, and is anticipated to register fastest CAGR of 8.8% during the forecast period. The growth is attributed to increasing number of geriatric populations, rising awareness regarding availability of healthcare services and growth in the number of chronic diseases. On the other hand, to tackle the severe drug problem in China, the government has adopted the Methadone Maintenance Treatment program, a multi-faceted therapeutic approach that aims to reduce the health and social problem created by drug epidemics. This will further help in fueling growth in this region.

On the other hand, lower opioid use is reported in Japan as compared to China. This makes Japan, the second biggest market for treatment of Opioid use disorder in this region. This country is projected to exhibit a CAGR of 7.9% during the forecast period. Factors such as growing government support for improving healthcare infrastructure, advancements in medical technology, and rising use of opioids in pain management by elderly population will aid in market expansion.

Category wise Insights

By drug type, which segment will possess market dominance?

Buprenorphine segment propelling growth with dominating share

This segment is estimated to dominate the market with an impressive 81.4% market share by end of the forecast period. This segment is also most likely to grow with the fastest CAGR of 9.2% during the projected period. The growth is attributable to the increasing usage of these drugs in developed markets, like in France and the United States.

Moreover, its high effectiveness in managing addiction, with low potential for abuse and relatively mild adverse effects, and its favorable formulary coverage, are factors that can be attributed to the increasing adoption of this drug. Buprenorphine/naloxone sublingual tablets, buprenorphine sublingual tablets, and branded Suboxone are the most widely prescribed drugs for the treatment of Opioid use disorder. Also, suboxone film is the most prescribed drug in Opioid disorder treatment market, owing to its excellent clinical profile. This will bolster the segment’s growth.

By Distribution Channel, which segment is most likely to dominate the market?

Hospitals driving growth with maximum market share

The hospital pharmacies are expected to dominate the market by accounting for 35% market share by end of the forecast period. This segment is anticipated to propel with a CAGR of 7.9% during the forecast period. Hospitals are the primary care facilities with abundant presence of well-trained, skilled staff and professionals who assist patients in receiving effective treatment.

Furthermore, adoption of prescribed therapy in clinics and hospitals helps in physician-supervised drug delivery. This is one of the major factors propelling sales of opioids via hospital pharmacies. Other medications, such as ‘naloxone’, which is an opioid-analgesic are made available in hospital pharmacies free of cost for easier access to patients with Opioid use disorders. All these factors are expected to fuel this segment’s growth.

Start-ups in Opioid use disorder treatment market

Start-ups help in understanding the outlook of any market. Start-ups also have the potential to generate higher returns which directly benefits in expansion of any market. This is because these are typically more efficient at converting inputs into outputs. These are more flexible and adaptable, able to shift quickly in response to changing market conditions. Some of the start-ups that will fuel the expansion of opioid use disorder treatment market are:

• Boulder Care is a Brooklyn, United states-based start-up that was founded in 2017. This start-up is an online platform that offers telehealth services for opioid use disorder. Any user can connect with a deaddiction specialist through phone or in person. The app offers a personalized clinical program created by a specialist based on the user's addiction. It also hosts information and resources to providers in managing the patients. It was granted total funding of USD 50 million from Qiming Venture Partners, Goodwater Capital, Tusk Ventures, Greycroft, Acumen and 5 others.
• Founded in 2018, Kaden is a Newyork, United States-based start-up. It is a data-driven digital behavioural health services company. The company's product combats the opioid addiction crisis by positively affecting human behavior and making advanced technologies and proven treatments reachable to all and delivers its Virtual Medication Assisted Treatment program through its network of affiliated providers. This company has been granted funding of USD 19.1 million till January 2023.
• Speranza Therapeutics is a United States-based start-up, founded in 2019. It develops FDA cleared devices for treating neurological disorders. It has developed an S.T. Genesis device which provides treatment therapy to reduce the physical and emotional strain for people suffering from opioid use disorder. This device is designed to manage auricular neurostimulation treatment and transmits electrical pulses emitted through needles strategically positioned in the ear. This device also provides an FDA-cleared Percutaneous nerve field stimulator device which supports the reduction of opioid withdrawal symptoms through application to branches of cranial nerves as well as the occipital nerves. This device makes a path from successful detoxification to complete recovery through a non-invasive intervention directly targeting opioid withdrawal symptoms.

Market Competition

The opioid use disorder treatment market is competitive and consists of several major players. Major players are creating novel delivery systems for the treatment of Opioid use disorder. This is expected to propel Opioid use disorder treatment market. The major players in the market are: Trevena, Opiate Pharmaceutical, Aphios, Kyowa kirin, Gamida-Cell, Novartis, Titan Pharmaceuticals, Inc., Hikma Pharmaceuticals, MediciNova, Alkermes, Inc., BioDelivery Sciences International, Inc. Key market players are concentrating on adoption of inorganic growth strategies such as acquisition, partnerships, and collaboration in order to improve their product portfolio. This is expected to propel the global Opioid use disorder treatment market.

Some recent developments in the market are:

• In January 2022, Trevena, Inc. declared that China’s National Medical Products Administration (NMPA) has accepted the submission of a New Drug Application (NDA) for OLINVYK (oliceridine) injection, a novel IV analgesic that has been approved in the United States by the FDA for use in adults for managing acute pain severe enough to require an intravenous opioid analgesic.
• In October 2021, Esteve Pharmaceuticals received authorisation from the United States Food and Drug Administration (FDA) for SEGLENTIS (celecoxib and tramadol hydrochloride) for the management of acute pain in adults that is extreme enough to require an opioid analgesic.
• In January 2020, Titan Pharmaceuticals, Inc. made a revelation that they had entered into an agreement with AllianceRx Walgreens Prime for the expansion of accessibility of patients for Titan’s opioid use disorder implant branded as “Probuphine implant”.

Report Scope

Report Attribute	Details
Market Value in 2023	USD 3.07 billion
Market Value in 2033	USD 8.4 billion
Growth Rate	CAGR of 10.5% from 2023 to 2033
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in USD billion and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered	Drug Type, Route of Administration, Distribution Channel, Region
Regions Covered	North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa
Key Countries Profiled	United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, China, Japan, Indonesia, Singapore, Thailand, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel
Key Companies Profiled	Trevena; Opiate Pharmaceutical; Aphios; Kyowa kirin; Gamida-Cell; Novartis AG; Titan Pharmaceuticals, Inc.; Hikma Pharmaceuticals; MediciNova; Alkermes, Inc.; BioDelivery Sciences International Inc.
Customization	Available Upon Request

Key Segments Profiled in the Opioid Use Disorder Treatment Market Survey

By Drug Type:

• Romiplostim
• Omidubicel
• Nalmefene
• Buprenorfine
• Methadone
• Naltrexone

By Route of Administration:

• Oral
• Parenteral

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East & Africa

Frequently Asked Questions

How Big will be the Market by 2033?

The market is estimated to achieve USD 8.4 billion by 2033.

What is the Growth Forecast for market?

The market is forecast to register a CAGR of 10.5% through 2033.

How the Market Developed in the Past?

From 2018 to 2022, the global market exhibited 7.89% HCAGR.

What is the Market Share of North America Through 2033?

A 48% of market share belongs to North America.

What is the Market CAGR For East Asia Through 2033?

During the forecast period, it is anticipated that East Asia experiences a CAGR of 8.8%.

What is the Leading Drug Type Segment in the Market?

The buprenorphine sector is expected to surge to a share of 81.4% by 2033.